
    
      Our scientific premise is that in women with endometriosis, elevated cardiovascular disease
      risk is the result of endothelial dysfunction and chronic systemic inflammation through
      lectin-like oxidized low-density lipoprotein receptor-1 (LOX-1) receptor activation. This
      cardiovascular disease risk is exacerbated by standard estrogen suppression treatments.
    
  